Abstract P259 – Table 1. Distribution of psychotropic drug concentrations in the 82 HIV‐infected patients of the GAP cohort and the 423 HIV‐negative controls receiving maintenance antidepressant and/or antipsychotic therapy

Psychotropic drug	HIV‐positive patients (n)	Daily drug doses	Trough levels (ng/mL)	Reference ranges (ng/mL)	Sub‐therapeutic samples (%)	HIV‐negative patients (n)	Trough levels (ng/mL)	Sub‐therapeutic samples (%)
Citalopram	15	10 to 20 mg	65 ± 67	50 to 110	60%a	50	73 ± 58	34%
Duloxetine	8	60 to 90 mg	32 ± 35	30 to 120	63%	19	68 ± 41	32%
Fluoxetine	5	20 to 40 mg	204 ± 190	120 to 500	50%	14	250 ± 160	21%
Paroxetine	13	20 to 40 mg	22 ± 20	20 to 65	54%	21	150 ± 116	33%
Sertraline	10	50 to 200 mg	20 ± 12	10 to 150	20%a	85	47 ± 43	6%
Venlafaxine	4	75 to 150 mg	223 ± 52	100 to 400	0%	44	288 ± 239	23%
Haloperidol	7	2 to 5 mg	1.4 ± 0.5	1 to 10	57%a	41	4.1 ± 2.6	5%
Olanzapine	8	2.5 to 20 mg	16 ± 16	20 to 80	88%a	37	47 ± 66	46%
Quetiapine	12	25 to 200 mg	266 ± 225	100 to 500	46%	112	211 ± 51	31%

ap < 0.05 versus HIV‐negative controls.